Oct 20, 2026 08:07AM
Oct 20, 2026 08:00AM
Oct 19, 2026 08:01AM
Oct 19, 2026 08:00AM
Oct 14, 2026 08:00AM
Sep 15, 2026 07:30AM
Sep 15, 2026 07:30AM BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Sep 14, 2026 04:01PM
Sep 14, 2026 04:01PM
Aug 6, 2026 07:30AM
Aug 6, 2026 07:30AM
May 27, 2026 08:00AM
May 26, 2026 08:01AM
May 26, 2026 08:00AM BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 18, 2026 08:01AM
May 18, 2026 08:00AM
Apr 27, 2026 08:00AM
Apr 27, 2026 08:00AM
Feb 23, 2026 08:00AM
Nov 19, 2025 08:00AM
Sep 26, 2025 08:00AM BioVie to Host Live Investor Webinar and Q&A on Oct. 8
Aug 13, 2025 04:05PM
Aug 13, 2025 04:05PM
Aug 11, 2025 04:05PM
Aug 11, 2025 04:05PM
Aug 7, 2025 08:43PM
Aug 7, 2025 08:43PM
Jul 24, 2025 08:01AM BioVie presents data on bezisterim's biological aging effects
Jul 24, 2025 08:00AM
Jul 22, 2025 09:05AM
Jul 22, 2025 08:00AM
Jul 9, 2025 08:00AM
Jun 26, 2025 08:00AM
Jun 24, 2025 04:05PM
May 15, 2025 08:00AM BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 14, 2025 07:30AM
May 7, 2025 08:00AM
May 5, 2025 08:02AM
May 5, 2025 08:00AM
Apr 16, 2025 08:00AM
Mar 27, 2025 08:00AM
Nov 20, 2024 08:00AM BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
Nov 4, 2024 08:00AM
Oct 29, 2024 04:05PM
Oct 28, 2024 04:10PM
Oct 28, 2024 04:10PM
Oct 28, 2024 03:15PM
Oct 28, 2024 03:13PM
Oct 24, 2024 04:10PM BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
Oct 23, 2024 03:25PM

455,347 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All